title: Progressively reducing regulatory burden.
abstract: Principles of dissolution science have been applied to allow waiver of in vivo bioequivalence studies for oral immediate release solid dosage forms, providing certain stipulations are met. This approach reduces regulatory burden without sacrificing product quality and performance requirements that assure continuing equivalence. These principles are broadly applicable to other dosage forms and routes of administration. In this article, we postulate a further opportunity, which relies on a determination of "optimal performance" for nonsolution orally administered drug products. The determination can be applied to certain highly soluble and rapidly dissolving drug products without further study, paving the way possibly for even further reductions in regulatory burden.
authors.affiliation: , N Potomac, Maryland, 20878, USA, dr.vpshah@comcast.net.
authors.forename: Vinod P
authors.initials: VP
authors.lastname: Shah
authors.forename: Todd L
authors.initials: TL
authors.lastname: Cecil
authors.forename: Srini V
authors.initials: SV
authors.lastname: Srinivasan
authors.forename: Roger L
authors.initials: RL
authors.lastname: Williams
mesh_terms: D001702:Biopharmaceutics; D004345:Drug Industry / Q000331:legislation & jurisprudence* / Q000639:trends*; D012995:Solubility; D013810:Therapeutic Equivalency
references.citation: AAPS J. 2013 Jan;15(1):41-52
references.pmid: 23054971
references.citation: Pharm Res. 1995 Mar;12(3):413-20
references.pmid: 7617530
references.citation: Adv Exp Med Biol. 1997;423:269-88
references.pmid: 9269503